PanCaVax · Personalised Pancreatic Cancer Vaccination Therapy derived from Autologous Tumor Cells and Neoantigens

CyTuVax B.V. is a biotech enterprise founded in Maastricht (the Netherlands) in October 2012. It applies depot-formulatedcytokines (interaction molecules of the immune system), which enhance immune responses in an unprecedented mannerwhen used in extremely high local density. Single and multi-cytokine combinations can be formulated by simple proceduresand act as strong adjuvants, driving immune responses to their limits. It is a universal, patented platform adjuvant technologythat can be applied to any vaccines and can have great influence on future vaccine technology. CyTuVax achieved the firstclinical proof of concept in a Phase I trial in which 90% of hepatitis B non-responders were successfully vaccinated. Phase IIis on-going. CyTuVax decided now to focus on the challenging problem of developing a vaccine for pancreatic cancer, adeadly disease for which no curative treatment exists. Its cancer vaccination therapy (PanCaVax) should substantiallyimprove the life-expectancy by extending the median survival rate to at least 12-24 months. Costs of PanCaVax will beconsiderably less compared to checkpoint inhibitor antibodies, with locally strong, but systemically mild, side effectsexpected. CyTuVax’ highly motivated team’s next step is to complete the preclinical development ofPanCaVax. Key impact of our innovation would be that it is providing a favorable clinical outcome and sufficient proof of efficacy to obtain financial resources for next steps in Phase IIb/IIIa, regulatory approval and ultimate access to pancreatic cancer patients currently lacking an acceptable therapy.